

## Notice of Zealand's interim report for H1 2016 and related conference call

---

- On the day of release, Thursday 25 August 2016 at 2.00pm CET, Zealand's senior management will host a conference call. The conference call can be accessed via live audio webcast from Zealand's website.

*Copenhagen, 17 August 2016* – Zealand Pharma (Zeland) confirms the release of its interim report for H1 2016 on Thursday 25 August 2016 in accordance with the company's financial calendar. The release can be expected in the morning.

### Conference call on Thursday, 25 August 2016 at 2.00pm CET

On the day of release, Zealand's senior management will host a conference call at 2.00pm CET to present the interim report for H1 2016. Participating in the call will be Britt Meelby Jensen, President and Chief Executive Officer, Mats Blom, SVP and Chief Financial Officer, Adam Steensberg, SVP and Chief Medical and Development Officer and Hanne Leth Hillman, SVP and Head of IR and Communications.

The presentation will be followed by a Q&A session.

The conference call will be conducted in English and the dial-in numbers are:

DK standard access	+45 32 71 16 60
UK and international	+44 (0) 20 7136 6283
US (free dial-in)	+1 646 254 3388

Kindly inform the operator of the following passcode: 7959175

A live audio webcast of the call including an accompanying slide presentation will be available via the following link, <http://edge.media-server.com/m/p/m4rcono7>, accessible also from the company's website ([www.zealandpharma.com](http://www.zealandpharma.com)). Participants are advised to register for the webcast approximately 10 minutes before the start.

A replay of the event will be made available from the Investor section of Zealand's website following the call.



### For further information, please contact:

**Hanne Leth Hillman**, Senior Vice President, Investor Relations and Communications  
Tel: +45 50 60 36 89, email: [hlh@zealandpharma.com](mailto:hlh@zealandpharma.com)



### About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq Copenhagen: ZEAL) ("Zealand") is a biotechnology company focused on the discovery, design and development of innovative peptide-based medicines. Zealand has a pipeline of proprietary product candidates which primarily target specialty disease areas with significant unmet medical needs and a portfolio of medicines and product candidates under license collaborations with Sanofi, Boehringer Ingelheim and Helsinn.

The company's first invented medicine, lixisenatide, a once-daily prandial GLP-1 analogue for the treatment of type 2 diabetes, is licensed to Sanofi. Lixisenatide is marketed globally outside the United States as Lyxumia® and approved in the U.S. as Adlyxin™. A fixed-ratio combination of lixisenatide with insulin glargine (Lantus®), referred to as iGlarLixi, is under regulatory review in the U.S. and in Europe.

Zealand's proprietary pipeline of product candidates includes: *Dasiglucagon\** (ZP4207) *single-dose rescue treatment* for acute, severe hypoglycemia (Phase II); *ZP1848* for short bowel syndrome (Phase II); *Dasiglucagon\** (ZP4207) *multiple-dose* intended for use in a dual-hormone artificial pancreas system for better hypoglycemia control and diabetes management (in preparation for Phase II); and other earlier stage clinical and preclinical peptide therapeutics.

Zealand is based in Copenhagen (Glostrup), Denmark. For further information about its business and activities, please visit [www.zealandpharma.com](http://www.zealandpharma.com) or follow Zealand on Twitter @ZealandPharma.

\* Dasiglucagon is a proposed International Nonproprietary Name (pINN).